Esperance Pharmaceuticals
company
About
Esperance Pharmaceuticals develops anticancer drugs that kill cancer cells without harming normal cells.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $7.50M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2006
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Esperance Pharmaceuticals is developing a new class of targeted anticancer drugs that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cell's surface. The drugs kill even those cells known to be resistant to chemotherapeutic drugs.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$19.70M
Esperance Pharmaceuticals has raised a total of
$19.70M
in funding over 2 rounds. Their latest funding was raised on
Jun 1, 2011 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 1, 2011 | Series B | $7.50M | 3 |
Sanofi
|
— | Detail |
| Nov 24, 2008 | Series A | $3.20M | 1 | — | — | Detail |
| Oct 31, 2006 | Series A | $9M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
Esperance Pharmaceuticals is funded by 3 investors.
Sanofi
and Advantage Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Sanofi
|
Yes | Series B |
Advantage Capital
|
— | Series B |
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
